GH Dec 2022 115.000 call
- Motley Fool
Why Guardant Health Stock Was So Healthy Today
Investors are cheered by the company's latest set of quarterly results, in spite of a deeper net loss.
- Business Wire
Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM™ Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer
PALO ALTO, Calif., August 05, 2022--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that studies utilizing its portfolio of blood tests and real-world data will be presented at the IASLC 2022 World Conference on Lung Cancer (WCLC 2022), hosted by the International Association for the Study of Lung Cancer, August 6-9 in Vienna, Austria. Among the 10 abstracts are oral presentations and posters highlighting the use of Guardant360™ to help physicians inform
- Zacks
Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates
Guardant Health (GH) delivered earnings and revenue surprises of -80% and 4.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
